HBV Mutation Detail Information

Virus Mutation HBV Mutation I126S


Basic Characteristics of Mutations
Mutation Site I126S
Mutation Site Sentence A G1896A and a T/I126S mutant are included in the positive samples.
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region S
Standardized Encoding Gene S  
Genotype/Subtype C
Viral Reference -
Functional Impact and Mechanisms
Disease Hepatitis B Virus Infection    
Immune Y
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information -
Treatment -
Location Korea
Literature Information
PMID 20347609
Title Establishment of an HBsAg mixed titer performance panel and HBsAg working standard for quality control of HBsAg diagnostic kits in Korea
Author Kwon SY,Cho NS,Cho YJ,Yoon KW,Choi KY,Park JS,Ryu S,Lee JH,Ha GW
Journal Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Journal Info 2010 Jun;48(2):109-14
Abstract BACKGROUND: International Standards or commercial panels used for performance validation of diagnostic kits might not reflect the viral characteristics common in Korea. Also, continuous use of these materials is difficult because of limited quantity and high cost. OBJECTIVES: Establishment of HBsAg reference materials to be used as National Standards for validation of HBsAg diagnostic kits. STUDY DESIGN: 568 plasma units with OD less than 2.0 on HBsAg EIA were collected. HBsAg testing with 3 EIAs and 1 CIA was performed on all units. HBsAg positive units were subjected to HBV DNA quantification, genotyping and subtyping. Candidates for the mixed titer performance panel and working standard were confirmed for HBsAg by neutralization. A collaborative study was conducted for the candidates of the mixed titer performance panel and the working standard. RESULTS: Based on the results of the collaborative study, a working standard (KFDA08/024) consisting of a series of four-fold dilutions of 2 materials, one with genotype/subtype C2/adr and the other with C1/adw, was established. A mixed titer performance panel composed of 2 negative and 16 positive samples was also established. A G1896A and a T/I126S mutant are included in the positive samples. CONCLUSIONS: An HBsAg mixed titer performance panel and a working standard reflecting HBV genotypes/subtypes prevalent in Korea have been established as National Standards. This will enable consistent supply of validation materials, improve the validation system of HBsAg diagnostic kits in Korea and lead to quality improvement of diagnostic kits.
Sequence Data -
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.